EFFICACY OF METHOTREXATE VERSUS LEFLUNOMIDE VERSUS COMBINATION OF BOTH IN ACTIVE RHEUMATOID ARTHRITIS

PAFMJ Pub Date : 2021-12-30 DOI:10.51253/pafmj.v6i6.4646
S. H. Tirmizi, A. Fakhr, Ahsan Amer, Kaswar Sajjad, K. Nawaz, A. Sharif
{"title":"EFFICACY OF METHOTREXATE VERSUS LEFLUNOMIDE VERSUS COMBINATION OF BOTH IN ACTIVE RHEUMATOID ARTHRITIS","authors":"S. H. Tirmizi, A. Fakhr, Ahsan Amer, Kaswar Sajjad, K. Nawaz, A. Sharif","doi":"10.51253/pafmj.v6i6.4646","DOIUrl":null,"url":null,"abstract":"Objective: To determine the efficacy of Methotrexate versus Leflunomide versus combination of both among patients managed at Pak Emirates Military Hospital with active rheumatoid arthritis. \nStudy Design: Prospective comparative study. \nPlace and Duration of Study: Rheumatology/General Medicine Department, Pak Emirates Military Hospital Rawalpindi, from May 2019 to June 2020. \nMethodology: Patient of active rheumatoid arthritis who fulfilled American college of rheumatology criteria of 1997 were included in the study. They were randomly divided into three groups with group A receiving Methotrexate, group B receiving Leflunomide while group C received the combination of both Methotrexate and Leflunomide. Disease activity was assessed by using the Disease Activity Score-28 in all the three groups after three months of treatment. \nResults: Mean age of the study participants was 36.919 ± 6.85 years. One hundred and fifty (83.3%) patients were female while 30 (16.7%) were male. Out of 160 (88.9%) patients achieved remission according to Disease Activity Score-28 score at the end of three months while 20 (11.1%) did not achieve remission. Pearson chi-square test revealed that none of the factors studied including the treatment option had any statistically significant relationship with presence of remission among the target population (p-value 0.386, 0.815, 0.194 and 0.145 for age, gender, duration of symptoms and type of treatment respectively). \nConclusion: Remission rate among the rheumatoid arthritis patients in response to treatment was overall good in the study. In terms of efficacy for symptoms of rheumatoid arthritis and achieving remission, after three months of treatment all the three options..................","PeriodicalId":19982,"journal":{"name":"PAFMJ","volume":"203 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PAFMJ","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51253/pafmj.v6i6.4646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: To determine the efficacy of Methotrexate versus Leflunomide versus combination of both among patients managed at Pak Emirates Military Hospital with active rheumatoid arthritis. Study Design: Prospective comparative study. Place and Duration of Study: Rheumatology/General Medicine Department, Pak Emirates Military Hospital Rawalpindi, from May 2019 to June 2020. Methodology: Patient of active rheumatoid arthritis who fulfilled American college of rheumatology criteria of 1997 were included in the study. They were randomly divided into three groups with group A receiving Methotrexate, group B receiving Leflunomide while group C received the combination of both Methotrexate and Leflunomide. Disease activity was assessed by using the Disease Activity Score-28 in all the three groups after three months of treatment. Results: Mean age of the study participants was 36.919 ± 6.85 years. One hundred and fifty (83.3%) patients were female while 30 (16.7%) were male. Out of 160 (88.9%) patients achieved remission according to Disease Activity Score-28 score at the end of three months while 20 (11.1%) did not achieve remission. Pearson chi-square test revealed that none of the factors studied including the treatment option had any statistically significant relationship with presence of remission among the target population (p-value 0.386, 0.815, 0.194 and 0.145 for age, gender, duration of symptoms and type of treatment respectively). Conclusion: Remission rate among the rheumatoid arthritis patients in response to treatment was overall good in the study. In terms of efficacy for symptoms of rheumatoid arthritis and achieving remission, after three months of treatment all the three options..................
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
甲氨蝶呤与来氟米特与两者联合治疗活动性类风湿关节炎的疗效
目的:确定在阿联酋军事医院治疗的活动性类风湿关节炎患者中甲氨蝶呤与来氟米特与两者联合治疗的疗效。研究设计:前瞻性比较研究。学习地点和时间:2019年5月至2020年6月,巴基斯坦拉瓦尔品第阿联酋军事医院风湿病科/综合医学科。方法:研究对象为符合1997年美国风湿病学会标准的活动性类风湿关节炎患者。随机分为A组甲氨蝶呤、B组来氟米特、C组甲氨蝶呤和来氟米特联合用药。治疗三个月后,三组患者的疾病活动度采用疾病活动度评分-28进行评估。结果:研究参与者的平均年龄为36.919±6.85岁。女性150例(83.3%),男性30例(16.7%)。在160例(88.9%)患者中,根据疾病活动评分(Disease Activity score -28)在3个月结束时达到缓解,而20例(11.1%)患者未达到缓解。皮尔逊卡方检验显示,包括治疗方案在内的所有研究因素与目标人群的缓解存在无统计学意义的关系(年龄、性别、症状持续时间和治疗类型的p值分别为0.386、0.815、0.194和0.145)。结论:类风湿关节炎患者对治疗的总体缓解率良好。就类风湿性关节炎症状的疗效和达到缓解而言,治疗三个月后,所有三种选择..................
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
COMPLICATIONS OF INTRA ABDOMINAL DRAINS: A SINGLE CENTER EXPERIENCE PATIENT AND OBSERVER SCAR ASSESSMENT FOLLOWING BASAL CELL CARCINOMA SURGERY: MULTICENTER QUASI EXPERIMENTAL STUDY Salivary Diagnosis of COVID-19 CHANGE OF NAME BY A PSYCHOTIC PATIENT: IS IT MANIFESTATION OF A PSYCHOPATHOLOGY MISSED UNTIL NOW? PRIMARY CNS LYMPHOMA MIMICKING TUBERCULOSIS INFECTION - A CASE REPORT
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1